好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Assessing Factors Influencing Seizure Self-Prediction in a Prospective Randomized Trial
Epilepsy/Clinical Neurophysiology (EEG)
P3 - Poster Session 3 (5:30 PM-6:30 PM)
6-024

To assess seizure precipitants and the value of electronic diary (E-diary) data in seizure prediction among patients with medication-resistant epilepsy (MRE).

Accurate seizure prediction would improve treatment and safety for people with epilepsy. Small studies utilizing a prospective written or E-diary approach have demonstrated an ability of select patients to predict occurrence of seizures with a common trigger being self-reported stress. As part of a multicenter, double-blind, randomized control trial to assess stress reduction for MRE, we evaluated factors associated with successful seizure self-prediction.

Patients were followed for 8-week baseline and 12-week treatment periods. Twice daily, participants rated the likelihood of a seizure in the next 24 hours on a 5-point scale from “very unlikely” to “almost certain”, along with mood, premonitory symptoms, stress ratings and seizure counts. A model of seizure prediction utilizing a gradient boosting algorithm calculated false detection and true positive rates of seizure occurrence based on these data. Seizure threshold scores were calculated to generate a relationship between these rates and a ROC curve was generated. Relative influence scores were generated to identify variables most predictive of seizure occurrence.

66 participants contributed data (3126 seizures) and had >85% diary adherence. E-diary data increased the true positive rates of seizure occurrence over a wide range of false detection rates. Subjective predictability increased following a seizure, suggesting some patients may be predicting “clusters” of seizures. Neither self-reported stress nor other reported precipitants were predictive factors in the model.  

Some patients with MRE are able to predict seizures to some extent. Prediction improved following seizures, suggesting some patients may be predicting “clusters” of seizures. Future studies should focus on understanding factors that drive seizure prediction and combine E-Diary with EEG and circadian data.

Authors/Disclosures
Jonathan A. Hartshorn, MD (Intermountain Healthcare)
PRESENTER
No disclosure on file
Sheryl R. Haut, MD (Albert Einstein College of Medicine) Dr. Haut has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB. Dr. Haut has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurelis. Dr. Haut has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ventus. Dr. Haut has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AbbieVe. Dr. Haut has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Iqvia.
Timothy J. Fries, MD (University of Vermont Medical Center) No disclosure on file
Michael D. Privitera, MD, FAAN (Univ of Cincinnati/Dept of Neurology) Dr. Privitera has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for SK life science. Dr. Privitera has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NeuroPace. Dr. Privitera has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for SK life science. Dr. Privitera has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Jazz. The institution of Dr. Privitera has received research support from Neurelis. The institution of Dr. Privitera has received research support from Biohaven. Dr. Privitera has received research support from Neurava.